Mandate

Vinge Advises Cyril Acquisitions in Offer for Cision

May 07, 2008

Cyril Acquisition AB, owned by Triton Fund II, has made official an offer to acquire all shares in Cision AB. Cyril Acquisition offer SEK 20 in cash for each share, and SEK 33,94 for each convertible profit share. Cision is listed on the OMX Nordic Exchange Stockholm AB, Mid Cap. Vinge has acted as the principal advisor in the transaction and handled the legal aspects connected to corporate law, finance, competition and due diligence.
 
Vinge's team included partner Johan Cederlund, Christina Kokko and Michael Ståhl, joined by associates Pontus Enquist and Petter Elmstedt concerning corporate issues, Sara Axelsson concerning financial issues, Björn Petersson in labour affairs, and Peter Forsberg and Hanna Eklinder regarding competition issues. Mi Gustafsson, Per Larsson and Tina Hård was engaged in the due diligence process.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024